Admission hyperglycemia and adverse outcomes in diabetic and non-diabetic patients with non-ST-elevation myocardial infarction undergoing percutaneous coronary intervention

Table 2 Clinical outcomes at 30 days and 3 years*

Variable Description	Participants without diabetes mellitus		Participants with diabetes mellitus
	Group1	Group 2	Group3	Group 4
	APG < 44 mg/dL n = 470	APG ≥144 mg/dL n = 184	APG < 180 mg/dL n = 133	APG ≥180 mg/dL n = 103
30-day outcomes (%)
Death, all-cause	2 (0.4)*^§ ⁺	7 (3.8)*^§ ⁺	3 (2.3)^# ^§ ⁺	9 (8.7)^# ^§ ⁺
Cardiac	2 (0.4)*^§ ⁺	6 (3.3)*^§ ⁺	2 (1.5)^# ^§ ⁺	8 (7.8)^# ^§ ⁺
Non-cardiac	0 (0.0)	1 (0.5)	1 (0.8)	1 (1.0)
Reinfarction	0 (0.0)	1 (0.5)	1 (0.8)	1 (1.0)
HF required hospital admission	3 (0.6)*^§ ⁺	5 (2.7)*^§ ⁺	2 (1.5)^# ^§ ⁺	6 (5.8)^# ^§ ⁺
Ischemic TVR	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Stroke	0 (0.0)*^§	2 (1.1)*^§	1 (0.8)^§	1 (1.0)^§
3-year outcomes (%)
Death, all-cause	17 (3.6)*^§ ⁺	20 (10.9)*^§+	13 (9.8)^# ^§ ⁺	20 (19.4)^# ^§ ⁺
Cardiac	14 (3.0)*^§ ⁺	17 (9.2)*^§ ⁺	12 (9.0)^# ^§ ⁺	19 (18.4)^# ^§ ⁺
Non-cardiac	3 (0.6)	3 (1.6)	1 (0.8)	1 (1.0)
Reinfarction	5 (1.1)*^§ ⁺	8 (4.3)*^§ ⁺	5 (3.8)^§ ⁺	9 (8.7)^§ ⁺
HF required hospital admission	16 (3.4)*^§ ⁺	22 (12.0)*^§ ⁺	15 (11.3)^§ ⁺	18 (17.5)^§ ⁺
Ischemic TVR	3 (0.6)	2 (1.1)	2 (1.5)	2 (1.9)
Stroke	4 (0.9)^§ ⁺	5 (2.7)^§ ⁺	2 (1.5)^§ ⁺	5 (4.9)^§ ⁺

APG admission plasma glucose, HF heart failure, TVR target lesion revascularization
*P < 0.05, Group 1 vs. Group 2
^# P < 0.05, Group 3 vs. Group 4
^§ P < 0.05, Group 1 vs. other three groups
⁺ P < 0.05, Group 4 vs. other three groups

ISSN: 1471-2261